Abstract:Background Nanobodies, named as VHHs (variable domain of heavy chain of HCAb [heavy-chain antibodies]), are derived from heavy-chain-only antibodies that circulate in sera of camelids. Their exceptional physicochemical properties, possibility of humanization, and unique antigen recognition properties make them excellent candidates for targeted delivery of biologically active components, including immunotoxins. In our previous efforts, we have successfully generated the monovalent and bivalent CD7 nanobody-based immunotoxins, which can effectively trigger the apoptosis of CD7-positive malignant cells. To pursue the possibility of translating those immunotoxins into clinics, we humanized the nanobody sequences (designated as dhuVHH6) as well as further truncated the Pseudomonas exotoxin A (PE)-derived PE38 toxin to produce a more protease-resistant form, which is named as PE-LR, by deleting majority of PE domain II. Methods and results Three new types of immunotoxins, dhuVHH6-PE38, dVHH6-PE-LR, and dhuVHH6-PE-LR, were successfully constructed. These recombinant immunotoxins were expressed in Escherichia coli and showed that nanobody immunotoxins have the benefits of easy soluble expression in a prokaryotic expression system. Flow cytometry results revealed that all immunotoxins still maintained the ability to bind specifically to CD7-positive T lymphocyte strains without binding to CD7-negative control cells. Laser scanning confocal microscopy revealed that these proteins can be endocytosed into the cytoplasm after binding with CD7-positive cells and that this phenomenon was not observed in CD7-negative cells. WST-8 experiments showed that all immunotoxins retained the highly effective and specific growth inhibition activity in CD7-positive cell lines and primary T-cell acute lymphoblastic leukemia (T-ALL) cells. Further in vivo animal model experiments showed that humanized dhuVHH6-PE38 immunotoxin can tolerate higher doses and extend the survival of NOD-Prkdcem26Il2rgem26Nju (NCG) mice transplanted with CEM cells without any obvious decrease in body weight. Further studies on NCG mice model with patient-derived T-ALL cells, dhuVHH6-PE38 treatment, significantly prolonged mice survival with ~40% survival improvement. However, it was also noticed that although dhuVHH6-PE-LR showed strong antitumor effect in vitro, its in vivo antitumor efficacy was disappointing. Conclusion We have successfully constructed a targeted CD7 molecule-modified nanobody (CD7 molecule-improved nanobody) immunotoxin dhuVHH6-PE38 and demonstrated its potential for treating CD7-positive malignant tumors, especially T-cell acute lymphoblastic leukemia.

Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.

[High Level Expression, Purification and Cytotoxicity of IL-10(18-57)-PE40].

The experimental study on the immunotoxin IL-10_(23-57-)PE40

Purification of clinical-grade disulfide stabilized antibody fragment variable— Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli

Expression and functional detection of recombinant immunotoxins anti-B7-H4-scFv/PE38KDEL

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL

Expression, purification, and refolding of a novel immunotoxin containing humanized single-chain fragment variable antibody against CTLA4 and the N-terminal fragment of human perforin.

Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines

[Construction and Prokaryotic Expression of a Recombinant Immunotoxin Fused with Mouse Interleukin 18 and Truncated Pseudomonas Exotoxin].

Design, Expression, Purification and Characterization of the Recombinant Immunotoxin 4D5 Scfv-Trail

An Efficient Scheme for Purification of a Novel Recombinant Immunotoxin, Rcck8pe38, for Anti-Tumour Experiments.

HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity

Study on the Preparation of the Immunotoxin 2E8-NCTD and Its Targeting Killing Effect in Vitro.

Molecular Construction and Characterization of a Novel Exotoxin Fusion Protein That Selectively Blocks the B7:CD28 Costimulatory Signal System

In Vitro and in Vivo Antitumor Effects of the Recombinant Immunotoxin IL6(T23)-PE38KDEL in Multiple Myeloma.

Data from Treatment of Hepatocellular Carcinoma in Mice with PE38KDEL Type I Mutant-Loaded Poly(lactic-Co-glycolic Acid) Nanoparticles Conjugated with Humanized SM5-1 F(ab′) Fragments

Manufacture and Evaluation of a HER2-positive Breast Cancer Immunotoxin 4D5fv-Pe25

Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential

Characterization of Recombinant Toxin rCCK96-104PE38 Targeting Colon Cancer

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

A novel immunotoxin - rCCK8PE38 targeting of CCK-R overexpressed colon cancers.